A modified immune effector cell may be one in which the functions of a T cell antigen receptor (TCR) and major histocompatibility complexes (MHCI, MHCII) in the modified immune effector cell are inhibited in a T cell. Such a modified immune effector cell may include a chimeric antigen receptor (CAR) targeting GD2. Such a modified immune effector cell may knock out TCR and HLA-A genes expressed by the cell while recognizing surface antigens of tumor cells, so that multiple effects of improving the anti-tumor effect of CAR-T cells, prolonging the survival time of the cells, and reducing the immune rejection response caused by allogeneic cell therapy may be reduced.

Chimeric Antigen Receptors (CARs) comprising a costimulatory sequence which is, or which is derived from, the intracellular domain of CD226, or a fragment thereof, are disclosed. Also disclosed are compositions comprising such CARs, and uses and methods using the same.

This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.

The present invention provides chimeric antigen receptors (CAR) and methods of use in the treatment of diseases and disorders.

The invention relates to the field of biomedicine, in particular to a T cell co-expressing CXCR2 and a Synthetic T-Cell Receptor and Antigen Receptor (STAR) against GPC3, and uses thereof.

The present invention relates to the field of biomedicine, to an improved T cell receptor-costimulatory molecule chimera, in particular to a T cell receptor (TCR) or TCR complex comprising a costimulatory molecule, a T cell comprising the TCR or TCR complex, and the use thereof.

The present disclosure provides immune effector cells engineered to express a functional exogenous receptor such as a CAR armored with a tumor homing peptide. The immune effector cells according to the present disclosure have enhanced tumor infiltration and anti-tumor efficacy.

The invention provides improved T cell compositions and methods for manufacturing T cells. More particularly, the invention provides methods of T cell manufacturing that result in adoptive T cell immunotherapies with improved survival, expansion, and persistence in vivo.

The present invention discloses humanized monoclonal antibodies that specifically bind to STn carbohydrate antigen with high specificity and selectivity, functional fragments of the humanized monoclonal antibodies such as scFv, conjugates and chimeric antigen receptors comprising the humanized monoclonal antibodies or the fragment thereof such as scFv. The invention further provides cells and compositions comprising the antibodies, fragments thereof or CARs as well as their use in diagnostics and treatment of cancer.

This disclosure provides bispecific antibody molecules that specifically bind to NKp46 and Glypican 3 (GPC3). The disclosure further relates to combination therapies comprising the bispecific antibody molecules. The bispecific antibody molecules can be used to treat, prevent and/or diagnose cancer or infectious conditions or disorders associated with cells expressing NKp46 and/or GPC3.